Conflict of interest or ideological divide: The need for ongoing collaboration between physicians and industry

Current Medical Research and Opinion

Volumn 22, Issue 9, 2006, Pages 1807-1812

  Duvall, David G ^a  

^a Clarus Health   (United States)

Author keywords

Academic medical center; ACCME; Conflict of interest; FDA; Health economics; OIG; Pharmaceutical industry; PhRMA

Indexed keywords

CONFLICT OF INTEREST; DRUG FORMULARY; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; IDEOLOGY; INTERPERSONAL COMMUNICATION; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; REVIEW; SAMPLING; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CONFLICT OF INTEREST; HEALTH CARE SECTOR; HUMANS; PHYSICIANS;

EID: 33749023345     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X120977     Document Type: Review

References (26)

1. Stossel TP. Regulating academic-industrial research relationships - solving problems or stifling progress? New Engl J Med 2005;353:1060-5
2. Brennan TA, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. J Am Med Assoc 2006;295:429-33
3. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? J Am Med Assoc 2000;283:373-80
4. Blumenthal D. Doctors and drug companies. New Engl J Med 2004;351:1885-90
5. Davis M, Stark A. Conflict of interest in the health professions. Oxford: Oxford University Press; 2001. p. 27
6. Kelch RP. Maintaining the public trust in clinical research. New Engl J Med 2002;346:285-7
7. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. New Engl J Med 2000;342:1539-44
8. Angell M. Is academic medicine for sale? New Engl J Med 2000;342:1516-8
9. DeAngelis C. Conflicts of interest and the public trust. J Am Med Assoc 2000;284:2237-8
10. Mello MM, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements with industry. New Engl J Med 2005;352:2202-10
11. Nathan DG, Weatherall DJ. Academic freedom in clinical research. New Engl J Med 2002;347:1368-71
12. Johns MM, Barnes M, Florencio PS. Restoring balance to industry-academia relationships in an era of institutional financial conflicts of interest: promoting research while main-taining trust. J Am Med Assoc 2003;289:741-6
13. Cho MK, Shohara R, Schissel A, Rennie D. Policies on faculty conflicts of interest at US universities. J Am Med Assoc 2000;284:2203-8
14. McCrary SV, Anderson CB, Jakovljevic J, et al. A national survey of policies on disclosure of conflicts of interest in biomedical research. New Engl J Med 2000;343:1621-6
15. Lo B, Wolf LE, Berkeley A. Conflict-of-interest policies for investigators in clinical trials. New Engl J Med 2000;343:1616-20
16. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. J Am Med Assoc 2003;289:454-65
17. Lurie P, et al. Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. J Am Med Assoc 2006; 295: 1921-9
18. Eli Lilly & Company. Milestones in medical research. Available at http://www.lilly.com/about/milestones.html [accessed June 15, 2006]
19. Gressor, M. Milestonesin medicine.February 17,2005.Availableat http://www.smh.com.au/articles/2005/02/17/1108500190027.html [accessed June 15, 2006]
20. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80: 827-41
21. Blumenthal D. The future of the academic medical center under health care reform. New Engl J Med 1993;329:1812-4
22. Pardes H. The perilous state of academic medicine. J Am Med Assoc 2000;283:2427-9
23. Moses H, Braunwald E, Martin JB, Their SO. Collaborating with industry - choices for the academic medical center. J Am Med Assoc 2002;347:1371-5
24. PhRMA code on interactions with health care professionals. Revised January 2004. Available at: http://www.phrma.org/publications/policy/2004-01-19. 391.pdf [accessed February 1, 2005]
25. Office of Inspector General. Compliance program guidance for pharmaceutical manufacturers. April 2003. Available at: http://oig.hhs.gov/ fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf [accessed February 1, 2005]
26. Accreditation Council for Continuing Medical Education. Standards for commercial support. Standards to ensure the independence of CME activities. Approved, September 2004. Available at: http://www.accme.org/dir_docs/ doc_upload/68b2902a-fb73-44dl-8725-80al504e520c_uploaddocument.pdf [accessed February 1, 2005]